|
|||||
|
|
Association of glucagon‐like peptide‐1 receptor agonist use and rates of acute myocardial infarction,stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system |
|
| Authors: | Robert S. Zimmerman MD Todd M. Hobbs MD Brian J. Wells MD PhD Sheldon X. Kong PhD Michael W. Kattan PhD Jon Bouchard MS Kevin M. Chagin MS Changhong Yu MS Brian Sakurada PharmD Alex Milinovich BA Wayne Weng PhD Janine M. Bauman BSN Kevin M. Pantalone DO |
| Affiliation: | 1. Endocrinology, Cleveland Clinic, Cleveland, Ohio;2. Novo Nordisk, Plainsboro, New Jersey;3. Clinical and Translational Science Institute, Wake Forest School of Medicine, Winston‐Salem, North Carolina;4. Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio |
| Abstract: | |
| Keywords: | glucagon‐like peptide‐1 receptor agonist cardiovascular risk cardiovascular disease mortality type‐2 diabetes |